Europe
BioArctic AB to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at 08:00 a.m. CET.
The century old mission to understand how the proteins responsible for amyloid-based diseases such as Alzheimer’s, Huntingdon’s and Parkinson’s work has taken major steps forward in the last 12 months, thanks to a revolution in a powerful microscopy technique used by researchers.
Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies
Global campaign to support 125 million people worldwide highlights the seriousness of psoriasis and psoriatic arthritis.
Theranexus announces today that it has recruited the last patient in its Phase II trial, entitled “Tolerance and Efficacy of THN102 on Sleepiness in Narcoleptic Patients”.
The 11th EFIB attracted around 240 companies and stakeholders from 31 nations. EMBRIC joined the conference to speak about and highlight the potential of the blue biotechnology.
MorphoSys AG will publish its third quarter 2018 results on November 5, 2018 at 10:00pm CET (9:00pm GMT; 4:00pm EST).
Full Antagonist Mechanism of Action Demonstrated In Vivo
Lamellar Biomedical Limited announces that Dr Alec McLean ,CEO, Dr Lynsey Howard (Head of Preclinical) and Steven Porteous (Head of Clinical and Regulatory) will be attending BIO-Europe 2018 in Copenhagen to introduce potential partners and investors to its cutting-edge LAMELLASOME™ technology.
Molecular diagnostic programme for better cancer treatment kicks off
PRESS RELEASES